Gemcitabine plus mitomycin C vs capecitabine plus mitomycin C
All‐cause mortality at 1 year · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus mitomycin C changes all‐cause mortality at 1 year compared with capecitabine plus mitomycin C (very low certainty).
1 finding from 1 review
- Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes onlyRR 1.14 [0.89, 1.48]1 study · 51 participantsVery low